Overview
No overview information available.
Background
No background information available.
Indication
用于高血压病及症状性高血压，冠心病、心绞痛、心肌梗塞、脑血栓、眩晕病、突发性耳聋的辅助性治疗。也可用于妇女更年期综合症。
Associated Conditions
No associated conditions information available.
Clinical Trials
Title | Posted | Study ID | Phase | Status | Sponsor |
|---|
No clinical trials found
No clinical trials found for this drug
FDA Drug Approvals
Approved Product | Manufacturer | NDC Code | Route | Strength | Effective Date |
|---|---|---|---|---|---|
| No FDA approvals found for this drug. | |||||
EMA Drug Approvals
Approved Product | Authorization Holder | Status | Issued Date |
|---|---|---|---|
| No EMA approvals found for this drug. | |||
HSA Drug Approvals
Approved Product | Manufacturer | Approval Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| No HSA approvals found for this drug. | |||||
NMPA Drug Approvals
Approved Product | Company | Approval Number | Drug Type | Dosage Form | Approval Date |
|---|---|---|---|---|---|
| Daidzein Tablets | 国药准字H11022303 | 化学药品 | 片剂 | 12/11/2020 | |
| Daidzein Tablets | 国药准字H44024969 | 化学药品 | 片剂 | 3/15/2024 | |
| Daidzein Tablets | 国药准字H14023545 | 化学药品 | 片剂 | 8/14/2020 | |
| Daidzein Tablets | 国药准字H31022797 | 化学药品 | 片剂 | 12/19/2019 | |
| Daidzein Tablets | 国药准字H22025591 | 化学药品 | 片剂 | 2/25/2020 | |
| Daidzein Tablets | 国药准字H21021233 | 化学药品 | 片剂 | 1/11/2022 | |
| Daidzein Tablets | 国药准字H41025037 | 化学药品 | 片剂 | 6/9/2020 | |
| Daidzein Tablets | 国药准字H14020875 | 化学药品 | 片剂 | 8/17/2020 | |
| Daidzein Tablets | 国药准字H44020987 | 化学药品 | 片剂 | 1/7/2020 | |
| Daidzein Tablets | 国药准字H20056033 | 化学药品 | 片剂 | 8/25/2020 |
PPB Drug Approvals
Approved Product | Registration No. | Company | Licence No. | Strength | Registration Date |
|---|---|---|---|---|---|
| No PPB approvals found for this drug. | |||||
TGA Drug Approvals
Approved Product | ARTG ID | Sponsor | Registration Type | Status | Registration Date |
|---|---|---|---|---|---|
| No TGA approvals found for this drug. | |||||